Statistics for Verve Therapeutics, (id:7785 VERV)

Valuation metrics

Market cap

436.18M

Enterprise value

-87,677,720.00

Trailing P/E (ttm)

-1.55

Forward P/E

-1.67

PEG ratio

-1.67

Price/Sales (ttm)

17.88

Price/Book (mrq)

0.81

Enterprise Value/Revenue

-3.59

Enterprise Value/EBITDA

0.40

Overview

Shares outstanding

84.66M

Float

62.44M

Shares short

17.23M

% Held by insiders

0.02%

% Held by institutions

0.90%

Average volume (10 days)

1.98M

Average volume (90 days)

Price summary

52-Week low

4.30

52-Week high

19.34

52-Week change

-138.35%

Beta

1.76

50-Day moving average

5.43

200-Day moving average

7.41

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

0.00%

Operating margin

-828.99%

Operational effectiveness

Return on assets

-22.19%

Return on equity

-40.67%

Income statement

Revenue (ttm)

0.30

Revenue per share (ttm)

0.30

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-219,971,008.00

Net income to common (ttm)

-197,026,000.00

Diluted EPS (ttm)

-2.46

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

539.92M

Total cash per share (mrq)

6.38

Total debt (mrq)

71.26M

Total Debt/Equity (mrq)

14.01

Current ratio (mrq)

1.30K%

Book value per share (mrq)

6.01

Cash flow

Cash flow statement

-157,527,008.00

Levered free cash flow (LFCF)

-93,179,128.00